Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types

Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types

Overexpression of the chondroitin sulfate proteoglycan 4 (CSPG4) has been associated with the pathology of multiple types of such as melanoma, breast cancer, squamous cell carcinoma, mesothelioma, neuroblastoma, adult and pediatric sarcomas, and some hematological cancers. CSPG4 has been reported to...

Full description

Bibliographic Details
Main Authors: Kristina M. Ilieva, Anthony Cheung, Silvia Mele, Giulia Chiaruttini, Silvia Crescioli, Merope Griffin, Mano Nakamura, James F. Spicer, Sophia Tsoka, Katie E. Lacy, Andrew N. J. Tutt, Sophia N. Karagiannis
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-01-01
Series:Frontiers in Immunology
Subjects:
CSPG4
MCSP
HMW-MAA
NG2
melanoma
triple-negative breast cancer
Online Access:http://journal.frontiersin.org/article/10.3389/fimmu.2017.01911/full

Internet

http://journal.frontiersin.org/article/10.3389/fimmu.2017.01911/full

Similar Items